Literature DB >> 24815691

MiR-718 represses VEGF and inhibits ovarian cancer cell progression.

Ruobing Leng1, Lang Zha2, Liangdan Tang3.   

Abstract

Oncogenic activation of VEGF is found in various malignancies, including ovarian cancer. In this study, we investigate the role of microRNA (miRNA) in the regulation of VEGF in ovarian cancer. We find that miR-718 is expressed at low levels and inversely correlates with VEGF expression in ovarian cancer specimens. MiR-718 also directly targets and represses VEGF expression. In addition, miR-718 restoration inhibits ovarian cancer proliferation both in vitro and in vivo. Moreover, VEGF expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phosphorylated AKT. These results suggest a new therapeutic strategy in ovarian cancer by restoring miR-718 expression, which is involved in VEGF regulation.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; MiR-718; Ovarian cancer; Proliferation; VEGF

Mesh:

Substances:

Year:  2014        PMID: 24815691     DOI: 10.1016/j.febslet.2014.04.040

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.

Authors:  Zhong-Dong Wang; Fan-Yong Qu; Yuan-Yuan Chen; Zhang-Shen Ran; Hai-Yan Liu; Hai-Dong Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

Review 2.  New ways to successfully target tumor vasculature in ovarian cancer.

Authors:  Xiaoyun Yang; Fangrong Shen; Wei Hu; Robert L Coleman; Anil K Sood
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927

3.  EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma.

Authors:  Juan Lu; Fei-Peng Zhao; Zengliu Peng; Meng-Wen Zhang; Shao-Xiong Lin; Bi-Jun Liang; Bao Zhang; Xiong Liu; Lu Wang; Gang Li; Wen-Dong Tian; Ying Peng; Ming-Liang He; Xiang-Ping Li
Journal:  Oncotarget       Date:  2014-11-30

4.  Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types.

Authors:  Fumiyasu Momose; Naohiro Seo; Yasushi Akahori; Shin-Ichi Sawada; Naozumi Harada; Toru Ogura; Kazunari Akiyoshi; Hiroshi Shiku
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

5.  Specific circulating microRNA signature of bicuspid aortic valve disease.

Authors:  Neus Martínez-Micaelo; Raúl Beltrán-Debón; Isabel Baiges; Marta Faiges; Josep M Alegret
Journal:  J Transl Med       Date:  2017-04-11       Impact factor: 5.531

6.  miR‑490‑5p regulates the proliferation, migration, invasion and epithelial‑mesenchymal transition of pharyngolaryngeal cancer cells by targeting mitogen‑activated protein kinase kinasekinase 9.

Authors:  Arikin Abdeyrim; Xiuqin Cheng; Meng Lian; Yuanyouan Tan
Journal:  Int J Mol Med       Date:  2019-05-13       Impact factor: 4.101

Review 7.  Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.

Authors:  Lízbeth Ayala-Domínguez; Leslie Olmedo-Nieva; J Omar Muñoz-Bello; Adriana Contreras-Paredes; Joaquín Manzo-Merino; Imelda Martínez-Ramírez; Marcela Lizano
Journal:  Front Oncol       Date:  2019-09-27       Impact factor: 6.244

8.  MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2.

Authors:  Grant A Howe; Kayla Kazda; Christina L Addison
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

9.  microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.

Authors:  Zhuo Yang; ZiYi Feng; JiaHui Gu; XinHui Li; QianZhe Dong; KuiRan Liu; Yan Li; Ling OuYang
Journal:  Oncotarget       Date:  2017-09-15

Review 10.  Possible Roles of Mitochondrial Dynamics and the Effects of Pharmacological Interventions in Chemoresistant Ovarian Cancer.

Authors:  Chalita Kingnate; Kittipat Charoenkwan; Sirinart Kumfu; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  EBioMedicine       Date:  2018-07-23       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.